Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Virotherapy Shows Promise Against Multiple Myeloma

Published: Friday, May 16, 2014
Last Updated: Friday, May 16, 2014
Bookmark and Share
A Mayo Clinic proof of principle clinical trial, demonstrated that virotherapy, destroying cancer with a virus that infects and kills cancer cells but spares normal tissues, can be effective against multiple myeloma.

Two patients in the study received a single intravenous dose of an engineered measles virus (MV-NIS) that is selectively toxic to myeloma plasma cells. Both patients responded, showing reduction of both bone marrow cancer and myeloma protein. One patient, a 49-year-old woman, experienced complete remission of myeloma and has been clear of the disease for over six months.

“This is the first study to establish the feasibility of systemic oncolytic virotherapy for disseminated cancer,” says Stephen Russell, M.D., Ph.D., Mayo Clinic hematologist, first author of the paper and co-developer of the therapy. “These patients were not responsive to other therapies and had experienced several recurrences of their disease.”

Multiple myeloma is a cancer of plasma cells in the bone marrow, which also causes skeletal or soft tissue tumors. This cancer usually responds to immune system-stimulating drugs, but eventually overcomes them and is rarely cured.

In their article, the researchers explain they were reporting on these two patients because they were the first two studied at the highest possible dose, had limited previous exposure to measles, and therefore fewer antibodies to the virus, and essentially had no remaining treatment options.

Oncolytic virotherapy – using re-engineered viruses to fight cancer – has a history dating back to the 1950s. Thousands of cancer patients have been treated with oncolytic viruses from many different virus families (herpesviruses, poxviruses, common cold viruses, etc.). However, this study provides the first well-documented case of a patient with disseminated cancer having a complete remission at all disease sites after virus administration. 

The second patient in the paper, whose cancer did not respond as well to the virus treatment, was equally remarkable because her imaging studies provided a clear proof that the intravenously administered virus specifically targeted the sites of tumor growth. This was done using high-tech imaging studies, which were possible only because the virus had been engineered with a 'snitch gene' — an easily identifiable marker — so researchers could accurately determine its location in the body.

More of the MV-NIS therapy is being manufactured for a larger, phase 2 clinical trial. The researchers also want to test the effectiveness of the virotherapy in combination with radioactive therapy (iodine-131) in a future study.

The findings appear in the journal Mayo Clinic Proceedings

Other authors include Mark Federspiel, Ph.D., Kah-Whye Peng, Ph.D., M.Med., Caili Tong, David Dingli, M.D., Ph.D., William Morice, M.D., Ph.D., Val Lowe, M.D., Michael O’Connor, Ph.D., Robert Kyle, M.D., Nelson Leung, M.D., Francis Buadi, M.D., S. Vincent Rajkumar, M.D., Morie Gertz, M.D., Martha Lacy, M.D., and senior and corresponding author Angela Dispenzieri, M.D., all of Mayo Clinic.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Wednesday, August 26, 2015
Mayo, Baylor Collaborate
They aim to study genomic links to drug metabolism and other interactions which could be used to provide more tailored patient care.
Friday, May 15, 2015
First Steps in Formation of Pancreatic Cancer Identified
Researchers at Mayo Clinic’s campus in Jacksonville say they have identified first steps in the origin of pancreatic cancer and that their findings suggest preventive strategies to explore.
Tuesday, November 11, 2014
Scientific News
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Imaging Software Could Speed Up Breast Cancer Diagnosis
Researchers use high speed optical microscopy of intact breast tissue specimens to analyze breast tissue.
A Metabolic Master Switch Underlying Human Obesity
Researchers find pathway that controls metabolism by prompting fat cells to store or burn fat.
Synthetic DNA Vaccine Against MERS Shows Promise
A novel synthetic DNA vaccine can, for the first time, induce protective immunity against the Middle East Respiratory Syndrome (MERS) coronavirus in animal species.
How Small RNA Helps Form Memories
In a new study, a team of scientists at Scripps Florida has found that a type of genetic material called "microRNA" (miRNA) plays surprisingly different roles in the formation of memory in animal models.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!